|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
WO1992018106A1
(fr)
|
1991-04-16 |
1992-10-29 |
Nippon Shinyaku Co., Ltd. |
Procede de production d'une dispersion solide
|
|
HU227530B1
(en)
|
1991-11-22 |
2011-07-28 |
Warner Chilcott Company |
Delayed-release compositions containing risedronate and process for their production
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
JP2616252B2
(ja)
|
1992-10-16 |
1997-06-04 |
日本新薬株式会社 |
ワックスマトリックスの製法
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
JPH11505258A
(ja)
|
1995-05-17 |
1999-05-18 |
セダーシナイ メディカル センター |
小腸における消化および吸収を改善させる脂肪酸を含む組成物
|
|
DE19624292A1
(de)
|
1996-06-18 |
1998-01-02 |
Merckle Gmbh |
Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
EP1767531A4
(en)
|
2004-06-10 |
2011-01-05 |
Torii Pharmaceutical Co Ltd |
6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
|
|
US20080305169A1
(en)
|
2006-05-26 |
2008-12-11 |
Japan Tobacco Inc. |
Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
|
|
BRPI0809843A2
(pt)
|
2007-04-26 |
2014-09-23 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
TWI377944B
(en)
|
2007-06-05 |
2012-12-01 |
Hanmi Holdings Co Ltd |
Novel amide derivative for inhibiting the growth of cancer cells
|
|
US8791077B2
(en)
|
2008-05-22 |
2014-07-29 |
Astrazeneca Ab |
Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
|
|
JP5325065B2
(ja)
|
2009-09-30 |
2013-10-23 |
株式会社富士薬品 |
新規フェノール誘導体
|
|
IT1400609B1
(it)
|
2010-05-10 |
2013-06-14 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e metformina e loro uso.
|
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
|
US20150031768A1
(en)
|
2011-08-19 |
2015-01-29 |
The Trustees Of Princeton University |
C-halogen bond formation
|
|
US9060987B2
(en)
*
|
2011-11-04 |
2015-06-23 |
Cymabay Therapeutics, Inc. |
Methods for treating gout flares
|
|
US9962362B2
(en)
|
2012-03-29 |
2018-05-08 |
Children's Hospital Medical Center |
Use of small molecule inhibitors targeting EYA tyrosine phosphatase
|
|
KR20210033067A
(ko)
*
|
2012-06-04 |
2021-03-25 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
|
WO2014113407A2
(en)
|
2013-01-16 |
2014-07-24 |
Children's Hospital Medical Center |
Use of small molecule inhibitors targeting eya tyrosine phosphatase
|
|
JP2016512817A
(ja)
|
2013-03-15 |
2016-05-09 |
ヤンセン ファーマシューティカ エヌ．ベー． |
高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
|
|
CN105579037A
(zh)
|
2013-05-31 |
2016-05-11 |
武田制药美国有限公司 |
用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
|
|
WO2015134467A1
(en)
|
2014-03-05 |
2015-09-11 |
The Trustees Of Princeton University |
Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
|
|
MX2017001103A
(es)
|
2014-07-31 |
2017-04-27 |
Merck Patent Gmbh |
Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
|
|
CN104311516B
(zh)
*
|
2014-09-16 |
2017-01-11 |
东北制药集团股份有限公司 |
一种苯溴马隆晶型b及其制备方法
|
|
CN104262305B
(zh)
*
|
2014-09-16 |
2016-06-08 |
东北制药集团股份有限公司 |
一种苯溴马隆晶型a及其制备方法
|
|
CN113214198B
(zh)
|
2016-07-18 |
2022-12-23 |
广州瑞安博医药科技有限公司 |
用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
|
|
WO2018090921A1
(zh)
|
2016-11-16 |
2018-05-24 |
江苏新元素医药科技有限公司 |
Urat1抑制剂及其应用
|
|
WO2018110887A1
(ko)
|
2016-12-14 |
2018-06-21 |
주식회사 엘지화학 |
헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
|
|
WO2019195118A1
(en)
|
2018-04-03 |
2019-10-10 |
Children's Hospital Medical Center |
Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
|
|
WO2019233459A1
(zh)
|
2018-06-08 |
2019-12-12 |
江苏威凯尔医药科技有限公司 |
人表皮生长因子受体抑制剂及其制备方法和应用
|
|
US20210338648A1
(en)
|
2018-10-01 |
2021-11-04 |
Astrazeneca Ab |
Methods and compositions for reducing serum uric acid
|
|
CA3121624A1
(en)
|
2018-12-06 |
2020-06-11 |
Arthrosi Therapeutics, Inc. |
Methods for treating or preventing gout or hyperuricemia
|
|
US12145917B2
(en)
|
2018-12-06 |
2024-11-19 |
Arthrosi Therapeutics, Inc. |
Crystalline forms of a compound for treating or preventing gout or hyperuricemia
|
|
EP3962908A4
(en)
|
2019-04-25 |
2022-10-26 |
Board of Regents, The University of Texas System |
HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
|
|
EP3968989A4
(en)
|
2019-05-14 |
2022-12-28 |
Arthrosi Therapeutics, Inc. |
COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA
|
|
CN112079830B
(zh)
|
2019-06-14 |
2023-12-22 |
上海翰森生物医药科技有限公司 |
含并环类衍生物抑制剂、其制备方法和应用
|
|
WO2021252630A1
(en)
|
2020-06-10 |
2021-12-16 |
Arthrosi Therapeutics, Inc. |
Methods for treating or preventing chronic kidney disease
|
|
CN111763215B
(zh)
|
2020-07-21 |
2021-05-18 |
成都海博为药业有限公司 |
一种具有含氮杂环结构的化合物及其制备方法和用途
|
|
CN112729156A
(zh)
|
2020-12-24 |
2021-04-30 |
上海智能制造功能平台有限公司 |
一种人体数字化测量装置的数据拼接及系统标定方法
|
|
CN114697265A
(zh)
|
2020-12-29 |
2022-07-01 |
华为技术服务有限公司 |
一种报文处理方法及装置
|
|
IL310870A
(en)
|
2021-08-24 |
2024-04-01 |
Arthrosi Therapeutics Inc |
Quinazoline compounds for treatment of disease
|
|
US20250066316A1
(en)
*
|
2021-12-02 |
2025-02-27 |
Arthrosi Therapeutics, Inc. |
Crystalline forms of a compound for treating or preventing gout or hyperuricemia
|
|
CN118974028A
(zh)
|
2021-12-30 |
2024-11-15 |
广州瑞安博医药科技有限公司 |
用于治疗痛风或高尿酸血症的化合物的制备
|